Business
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
Seasoned leaders bring deep experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets as company continues to advance clinical pipelineBOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Sil
About this update from Leonabio, Inc.
[{"type":"image","alt":"LeonaBio, Inc.","displaySize":"","headline":null,"caption":"LeonaBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/93f8813649f53adab50c69bb82ec5c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uwxNQTYMGJ48UT595lZOXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/93f8813649f53adab50c69bb82ec5c47","width":300,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/uwxNQTYMGJ48UT595lZOXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/93f8813649f53adab50c69bb82ec5c47","width":300,"height":89}},"lazy":false},{"type":"text","content":"Seasoned leaders bring deep experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets as company continues to advance clinical pipeline","length":195,"tagName":"p"},{"type":"text","content":"BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective as of May 5, 2026. The company also announced that John Fluke, Jr., who has served on the Board of Directors since 2014, retired effective May 4, 2026.","length":506,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Fred, Natalie, and Peter to LeonaBio’s Board of Directors,” said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. “Collectively, they bring significant drug development experience across different oncology and neurology settings, proven leadership in corporate strategy and operational execution, and capital markets expertise. Their backgrounds and capabilities are directly aligned with our clinical focus and will be instrumental as we advance our pipeline and position the company for its next phase of growth.”","length":566,"tagName":"p"},{"type":"text","content":"“On behalf of the Board of Directors and management team, I would also like to express our sincere appreciation to John Fluke for his thoughtful counsel and dedicated service over the past decade. His ...